Neuphoria Therapeutics (NEUP) Non-Current Receivables (2021)
Neuphoria Therapeutics (NEUP) reported Non-Current Receivables of $17841.0 for Q4 2021, down 88.43% on a QoQ basis from $154174.3 in Q2 2021.
Neuphoria Therapeutics (NEUP) has 1 years of Non-Current Receivables data on file, last reported at $17841.0 in Q4 2021.
- Quarterly Non-Current Receivables changed N/A year-over-year to $17841.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $17841.0 (changed N/A YoY) and the FY2021 annual result came in at $154174.3, changed N/A from the prior year.
- Non-Current Receivables declined to $17841.0 in Q4 2021 per NEUP's latest filing, from $154174.3 in the prior quarter.
- Across five years, Non-Current Receivables topped out at $154174.3 in Q2 2021 and bottomed at $17841.0 in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.49 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 17,840.98 |
| Jun 30, 2021 | 154,174.28 |